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Diabetes is a recognized risk factor of incre-
ased morbidity and mortality especially in patients
with ischemic heart disease and after myocardial
infarction [1]. The need for early diagnosis and treat-
ment of diabetes is well recognized, but still seems
to be underappreciated. Hyperglycemia is frequently
lingering for a long time before fully apparent diabe-
tes is identified. Hyperglycemia is the key factor in
the pathogenesis of diabetic cardiomyopathy and
atherosclerosis observed in coronary and periphe-
ral vasculature [1–3]. The estimations from the
American Diabetes Association indicate that about
57 million (19%) Americans have prediabetes (fa-
sting glucose between 100–125 mg/dL) and 24 mi-
llion (8%) have diabetes [4]. It means that over
one-quarter of the US population is affected by hy-
perglycemia. Hyperglycemia leads not only to ad-
vanced and disseminated coronary disease but it
also triggers adverse mechanisms resulting in
myocardial fibrosis and collagen deposition in the
myocardium, recognized clinically as diastolic
dysfunction [5].
In this issue of “Cardiology Journal”, Gąsior
et al. [6] present an important study evaluating the
prognostic significance of blood glucose levels eva-
luated at admission to the hospital in a large cohort
of 1,310 acute ST-elevation myocardial infarction
patients. Briefly summarizing primary findings,
26.9% of patients were diagnosed with diabetes, and
82% of these patients had hyperglycemia (defined
as glucose level > 140 mg/dL). Among the rema-
ining 958 patients without diabetes, hyperglycemia
was detected in 39.5% patients. This observation
emphasizes that a very significant proportion of
patients admitted for acute myocardial infarction
might have unrecognized prediabetic state or even
diabetes. It is possible that an incidental glucose
elevation might be related to a stress and catecho-
lamine surge in the setting of chest pain and acute
myocardial ischemia. It also could be that some of
these individuals were not in fasting state for prior
few hours but it is unlikely that such a high num-
ber of patients had glucose elevation > 140 mg/dL
as an expression of adrenergic response or diet.
A limitation of this retrospective study includes lack
of follow-up data regarding diagnostic tests for dia-
betes. Nevertheless, this study raises awareness of
the magnitude of the problem, underappreciated by
family physicians or cardiologists.
This study also importantly stresses that the
risk of hyperglycemia in nondiabetic patients in the
setting of acute myocardial infarction should not be
neglected. What should clinicians learn from the
study of Gąsior et al. [6]? First of all, elevated glu-
cose levels might be considered as a marker of
multivessel and frequently disseminated coronary
disease, which is associated with more advanced
myocardial damage and worse outcome. In-hospi-
tal mortality in patients with acute myocardial in-
farction with multivessel disease is elevated. In the
study by Gąsior et al. [6] non-diabetic patients with
hyperglycemia had six-fold higher mortality that
those without hyperglycemia. The long-term mor-
tality was also two-fold higher. Therefore, these
patients after myocardial infarction should be direc-
ted to special track of aggressive monitoring and
treatment including aggressive statin therapy, glu-
cose control, in addition to standard measures used
in postinfarction patients including cardiac rehabi-
litation, described so elegantly by Piotrowicz and
Wolszakiewicz [7] in the same issue of the journal.
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The study by Gąsior et al. [6] also indicates the
need for prophylactic screening for diabetes, which
should be systematically done at older age and re-
gardless of age in patients with signs and symptoms
of ischemic heart disease. Systematic screening is
likely to identify a significant number of patients
with diabetes or pre-diabetic states, conditions
which would require counseling regarding weight,
diet, exercise, and treatment, if needed [8]. This
proactive approach will contribute to an earlier dia-
gnosis of metabolic conditions leading to a progres-
sion of atherosclerosis, acute coronary syndromes,
and diabetic myocardial remodeling. There are al-
ready known large benefits of restrictions related
to smoking in public places measured by significant
decline in a number of patients admitted to hospi-
tals due to acute coronary syndromes [9]. Diabetes
and pre-diabetic states are the next big challenge
of public health systems, especially in light of gro-
wing obesity in modern societies. The implemen-
tation of widespread use of proactive measures
aiming to diagnose and treat metabolic syndrome,
pre-diabetic states, and diabetes is likely to bring
similar effects to those observed after restriction
of smoking or replacement of animal fats in diets.
We also learned from the study by Gąsior et al. [6]
that their diabetic patients had mean blood glucose
levels of 253 mg/dl, which again could be exacerba-
ted by stress, but this level definitely calls for con-
sidering more aggressive therapy in patients with
diabetes in the chronic setting. Under-controlled
diabetes is one of the important prerequisites for
development of vascular and myocardial complica-
tions of diabetes. Postinfarction patients with dia-
betes and also those with elevated glucose levels
have increased risk of recurrent coronary syndro-
mes. In the analysis of 918 stable postinfarction
patients from the THROMBO study [10], we found
that 151 of 749 (20%) of nondiabetic patients had
fasting glucose ≥ 100 mg/dL levels measured
2 months after myocardial infarction. One could
argue whether this threshold is too liberal but ac-
cording to the American Diabetes Association pre-
diabetes is diagnosed when fasting glucose levels
ranges from 100–125 mg/dl. These patients had
a mean fasting glucose level of 120 ± 27 mg/dL.
Figure 1 shows the cumulative probability of cardiac
events defined as unstable angina requiring hospi-
talization, nonfatal myocardial reinfarction or death
in postinfarction patients from enrollment (2 mon-
ths after myocardial infarction). Patients were iden-
tified as those with treated diabetes, no diabetes and
no glucose elevation, and no recognized diabetes but
with fasting glucose ≥ 100 mg/dL. A 2-year event rate
(which was a mean follow-up in this study) was 32%
in diabetic patients, 23% in non-diabetic patients with
elevated glucose, and 17% in nondiabetic patients
with glucose < 100 mg/dL. Although the difference
between the two latter groups did not reach signifi-
cance, there was a clear trend indicating that patients
similar to those reported by Gąsior et al. [6] have
worse outcome that those with low levels of gluco-
se even when evaluated in a stable postinfarction
period, not in acute phase of myocardial infarction.
Figure 1. Cumulative probability of cardiac events defined as unstable angina requiring hospitalization, nonfatal
myocardial reinfarction, or death in 918 stable postinfarction patients with diabetes, elevated glucose (no diabetes
recognized), and no diabetes (no elevated glucose). Of note, despite a clear trend, there is no significant difference
between two lower curves.
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Elevated blood glucose level in postinfarction
and ischemic heart disease patients remains an
underappreciated clinical parameter. A more pro-
active approach to detecting and addressing hyper-
glycemia and diabetes could significantly change the
practice of medicine and could influence the epide-
miology of cardiovascular morbidity and mortality
in general. Preventing diabetic cardiomyopathy and
vasculopathy will be as rewarding as restriction of
smoking.
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